Caliway Biopharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	49.98	38.93	12.82	12.34	10.35	18.65
Revenue Growth (YoY)	64.40%	203.68%	3.90%	19.22%	-44.50%	-
Cost of Revenue	15.31	11.46	3.21	3.11	3.68	7.84
Gross Profit	34.67	27.47	9.61	9.23	6.68	10.81
Selling, General & Admin	82.58	36.95	34.21	59.35	23.29	23.8
Research & Development	652.63	503.99	295.02	180.62	88.98	109.14
Operating Expenses	735.21	540.94	329.23	239.97	112.28	132.94
Operating Income	-700.55	-513.47	-319.62	-230.73	-105.6	-122.13
Interest Expense	-0.37	-0.5	-0.67	-2.9	-4.51	-3.69
Interest & Investment Income	35.36	17.42	5.19	0.1	0.04	0.02
Currency Exchange Gain (Loss)	-0.77	-1.03	14.23	-1.07	5.87	-0.31
Other Non Operating Income (Expenses)	15.34	9.12	14.83	10.34	5.81	4.31
EBT Excluding Unusual Items	-651	-488.46	-286.05	-224.26	-98.4	-121.8
Gain (Loss) on Sale of Assets	-	-	-0.11	-	-	-
Pretax Income	-651	-488.46	-286.16	-224.26	-98.4	-121.8
Income Tax Expense	-	-	-	0.03	0.09	0.03
Net Income	-651	-488.46	-286.16	-224.29	-98.49	-121.83
Net Income to Common	-651	-488.46	-286.16	-224.29	-98.49	-121.83
Shares Outstanding (Basic)	136	124	117	92	74	70
Shares Outstanding (Diluted)	136	124	117	92	74	70
Shares Change (YoY)	10.76%	5.77%	27.35%	23.49%	6.52%	-
EPS (Basic)	-4.78	-3.94	-2.44	-2.44	-1.32	-1.74
EPS (Diluted)	-4.78	-3.94	-2.44	-2.44	-1.32	-1.74
Free Cash Flow	-615.58	-432.54	-256.93	-125.6	-47.24	-106.53
Free Cash Flow Per Share	-4.52	-3.49	-2.19	-1.37	-0.63	-1.52
Gross Margin	69.37%	70.56%	74.94%	74.83%	64.49%	57.96%
Operating Margin	-1401.74%	-1318.88%	-2493.17%	-1869.95%	-1020.30%	-654.87%
Profit Margin	-1302.60%	-1254.64%	-2232.10%	-1817.76%	-951.56%	-653.27%
Free Cash Flow Margin	-1231.73%	-1111.01%	-2004.12%	-1017.90%	-456.41%	-571.23%
EBITDA	-679.48	-493.68	-302.36	-214.49	-94.43	-106.7
D&A For EBITDA	21.07	19.79	17.26	16.24	11.17	15.44
EBIT	-700.55	-513.47	-319.62	-230.73	-105.6	-122.13

Source: S&P Capital IQ. Standard template. Financial Sources.